RxDoctor Payments Data

Mary Gerard, MD

Neurology · Pocatello, IDNPI 1578667739

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 54.3% of the total. That places this record below the midpoint for neurology clinicians in ID, where the typical reported total is $1,243.

$521in general payments, 2019–2025

Across 28 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$283
  • Bristol Myers Squibb$55
  • Medtronic$35
  • Lilly USA, LLC$34
  • Nalu Medical, Inc.$34
  • Cala Health, Inc.$24
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$521 in reported general payments places this provider in the 35th percentile of 59 neurology providers in Idaho.

See all neurology providers in Idaho

Medicare billing

Part B allowed, 2024
$67,848
Medicare patients
228
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate23$131,660
TecfideraDimethyl Fumarate13$125,044
Dimethyl Fumarate45$103,023
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$102,493
NuplazidPimavanserin Tartrate12$56,611
NeuproRotigotine18$24,647
Emgality PenGalcanezumab-Gnlm28$24,091
Entacapone93$17,233
VimpatLacosamide11$16,561
Aimovig AutoinjectorErenumab-Aooe20$14,718
Lacosamide40$12,918
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone57$11,556
Rivastigmine55$10,790
Lamotrigine ErLamotrigine15$10,612
Carbidopa-LevodopaCarbidopa/Levodopa200$4,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$13$131,66023 claims
PfizerDilantin$14$2,97135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 59 neurology providers in Idaho.

Other neurology in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →